Genetics and Genomics
Meet with us for compelling content and renewed connections at AHA Scientific Sessions 2021. In-person Event in Boston, Massachusetts + Virtual Experience, Saturday, November 13-15.
Abstract presentations are a key component of AHA Scientific Sessions. Abstract presenters have the option to present in person in Boston or as a part of the virtual experience.
The incentive to disseminate the latest cardiovascular and stroke science to colleagues around the world has never been greater.
Clinicians and Scientists thrive on collaboration and sharing their study findings. Present your innovative research to a global audience at Scientific Sessions, the world's premier cardiovascular conference.
We know your work is vital to saving lives. Share it with fellow researchers, clinicians, and scientists.
The GPM Council seeks to advance discovery and translation of biological insights from genetics and omics technologies to improve cardiovascular and brain health through better risk prediction, treatment and prevention for patients. Our expertise spans genetics, genomics, genomic medicine, epigenetics, transcriptomics, metabolomics, proteomics, microbiome, bioinformatics, computational science, and population health.
Since 1999, the BCVS Council has advanced understanding of mechanisms of basic cardiovascular regulation to support insights into cardiovascular disease and facilitate new therapies. Emphasis is on integrating molecular/cellular and physiological approaches to address problems relating to genomics, cell signaling, myocardial biology, circulatory physiology, pathophysiology, and peripheral vascular disease.
The ATVB Council focuses on arteriosclerosis, thrombosis and vascular biology. The council advances research, addresses prevention, improves diagnosis and treatment, and works actively with other organizations. It shares reliable information through its annual conference, awards and lectures, and in the AHA’s journal, Arteriosclerosis, Thrombosis, and Vascular Biology.
Results: ORION-9 with Frederick Raal, PhD
Derick Raal, PhD, principal Investigator of the ORION-9 trial provides a brief overview of the results and their significance for patients with familial hypercholesterolemia. Dr. Raal is on the faculty of Health Sciences at the University of the Witwatersrand in Johannesburg, South Africa.